ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC's support for the MOSA, a pan-African randomized platform ad ...
After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it ...
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...
Emergent BioSolutions (EBS) announces that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...
Hosted on MSN6d
EBS obtains rights to Hikma's Kloxxado naloxone sprayEmergent BioSolutions (NYSE:EBS) has entered into an agreement for the exclusive commercial rights in the U.S. and Canada for ...
Hikma Pharmaceuticals PLC, the multinational pharmaceutical group, has entered an exclusive commercial partnership with ...
7d
Hikma Pharmaceuticals plc (HIK, HIK.L) announced Tuesday that it has entered an exclusive commercial partnership with Emergent ...
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...
A leader in innovative aging-in-place solutions, Vyta?Powered by Bayshore HealthCare is proud to announce a groundbreaking ...
The Japanese Embassy in Manila advised FIlipino tourists to file their visa application two months before their expected ...
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback